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Abstract
 
Prostaglandin E (PGE)2 produced by osteoblasts acts as a potent stimulator of bone resorption.
Inflammatory bone loss is accompanied by osteoclast formation induced by bone-resorbing cy-
tokines, but the mechanism of PGE2 production and bone resorption in vivo is not fully un-
derstood. Using cytosolic phospholipase A2
 
  
 
(cPLA2
 
 
 
)-null mice, we examined the role of
cPLA2
 
  
 
in PGE2 synthesis and bone resorption. In bone marrow cultures, interleukin (IL)-1
markedly stimulated PGE2 production and osteoclast formation in wild-type mice, but not in
cPLA2
 
 
 
-null mice. Osteoblastic bone marrow stromal cells induced the expression of cycloox-
ygenase (COX)-2 and membrane-bound PGE2 synthase (mPGES) in response to IL-1 and li-
popolysaccharide (LPS) to produce PGE2. Osteoblastic stromal cells collected from cPLA2
 
 
 
-
null mice also induced the expression of COX-2 and mPGES by IL-1 and LPS, but could not
produce PGE2 due to the lack of arachidonic acid release. LPS administration to wild-type
mice reduced femoral bone mineral density by increased bone resorption. In cPLA2
 
 
 
-null
mice, however, LPS-induced bone loss could not be observed at all. Here, we show that
cPLA2
 
  
 
plays a key role in PGE production by osteoblasts and in osteoclastic bone resorption,
and suggest a new approach to inflammatory bone disease by inhibiting cPLA2
 
 
 
.
Key words: cPLA2
 
 
 
 • bone loss • osteoclast • osteoblast • lipopolysaccharide
 
Introduction
 
Prostaglandin E (PGE)
 
*
 
2 is produced in bone mainly by
osteoblasts and acts as a potent stimulator of bone resorp-
tion (1–3). The production of PGE2 by osteoblasts is regu-
lated by several cytokines, including IL-1 and IL-6. We
have reported that PGE2 stimulated adenylate cyclase in
mouse osteoblasts to accumulate cellular cAMP, induced
osteoclast formation in mouse bone marrow cultures, and
stimulated bone resorption in mouse calvarial cultures (4–
6). The addition of indomethacin, an inhibitor of prosta-
glandin (PG) synthesis, to mouse bone marrow cultures
strikingly suppressed osteoclast formation induced by IL-1,
indicating that PGE2 production by osteoblasts is involved
in the mechanism of bone resorption induced by IL-1 (5, 6).
PGE2 synthesis is regulated by three metabolic steps: the
release of arachidonic acid from the membranous phospho-
lipids by phospholipase A2 (PLA2), the conversion of
arachidonic acid to PGH2 by cyclooxygenase (COX), and
the synthesis of PGE2 by PGE synthase (PGES; 7–13). We
have previously reported that cytosolic PLA2
 
  
 
(cPLA2
 
 
 
) is
constitutively expressed in mouse osteoblasts and is a key
enzyme in IL-1–induced PGE2 synthesis after its activation
by platelet-derived growth factor (6). Although both con-
stitutive COX (COX-1) and inducible COX (COX-2) are
expressed in mouse osteoblasts, the expression of COX-2 is
markedly induced by several bone-resorbing factors, in-
cluding IL-1 in osteoblasts. The addition of NS-398, a se-
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*
 
Abbreviations used in this paper:
 
 BMD, bone mineral density; BV/TV,
 
bone volume/tissue volume; COX, cyclooxygenase; cPLA2
 
 
 
, cytosolic
phospholipase A2
 
 
 
; EIA, enzyme immunoassay; mPGES, membrane-bound
prostaglandin E synthase; PG, prostaglandin; PGE, prostaglandin E; PGES,
PGE synthase; PLA2, phospholipase A2; RANKL, receptor activator of nu-
clear factor 
 
 
 
B ligand; Tb.Sp, trabecular separation; Tb.Th, trabecular thick-
ness; TLR, Toll-like receptor; TRAP, tartrate-resistant acid phosphatase.T
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lective inhibitor of COX-2, inhibits the IL-1–induced
PGE2 synthesis (5, 6). Two PGES, membrane-bound
PGES (mPGES) and cytosolic PGES have been recently
cloned (11–13). The expression of mPGES is greatly in-
duced by LPS in rat peritoneal macrophages and by IL-1/
TNF in rat osteoblasts. Therefore, cPLA2
 
 
 
, COX-2, and
mPGES might be requisite for the regulation of PGE2 syn-
thesis in response to IL-1 in mouse osteoblasts and bone
marrow stromal cells.
It is known that the administration of LPS not only in-
duces inflammation with fever but also osteoclastic bone
resorption (14, 15). In macrophages, LPS binds to LPS re-
ceptors, called toll-like receptor (TLR)4, and induces the
production of cytokines such as IL-1 and TNF
 
 
 
, and the
COX-2–mediated PG synthesis (16, 17). However, it is
not known whether LPS acts on osteoblasts to elicit PGE2
production. Because LPS could induce bone loss in vivo,
LPS-induced PGE2 production by osteoblasts might be in-
volved in the mechanism of bone resorption associated
with inflammation.
Although PLA2 is a key enzyme in eicosanoid produc-
tion, mammalian cells contain structurally diverse forms of
PLA2 including secretory PLA2, calcium-independent
PLA2, and cPLA2
 
  
 
(18, 19). To clarify the role of cPLA2
 
 
 
in eicosanoid production and its biological significance,
two groups, at the same time, have developed cPLA2
 
 
 
-
deficient mice by targeted disruption of the cPLA2
 
  
 
gene.
We generated cPLA2
 
 
 
-null mice and reported that the al-
lergic responses in the bronchopulmonary system were sig-
nificantly reduced in cPLA2
 
 
 
-null mice (20). Bonventre et
al. (21) showed a decrease in pathophysiological neuronal
death after transient focal cerebral ischemia in cPLA2
 
 
 
-null
mice. In either case, stimulated peritoneal macrophages
from cPLA2
 
 
 
-null mice failed to produce eicosanoids such
as PGE2, leukotriene B4, or leukotriene C4, and platelet-
activating factor, and the female cPLA2
 
 
 
-null mice failed
to deliver offspring due to defective reproductive systems
including pregnancy and labor (20, 21).
We examined the role of cPLA2
 
  
 
in PG synthesis and
bone resorption associated with inflammation both in vitro
and in vivo. To achieve our aim, using cPLA2
 
 
 
-null and
wild-type mice, PGE2 production and osteoclast formation
were determined in bone marrow cultures treated with
IL-1 in vitro, and LPS-induced bone resorption was ana-
lyzed in vivo.
 
Materials and Methods
 
Animals and Reagents.
 
cPLA2
 
 
 
-null mice were established by
gene targeting (20). Mice heterozygous for the cPLA2
 
  
 
mutant
allele with the genetic background of the C57BL/6J 
 
  
 
129/Ola
hybrid were mated and the genotypes of the mice were deter-
mined by PCR using genomic DNA isolated from the tail tip as
previously reported (20). At 6–8 wk of age, cPLA2
 
 
 
-null and
wild-type mice were used. Both female and male littermates were
used and the mice were matched for sex in each group. In some
experiments, mice were injected with LPS (5 mg/kg of body
weight) intraperitoneally on days 0 and 4 and the femurs were
collected on day 8. Mice in the control group were injected with
PBS. There was no significant difference in body weight between
cPLA2
 
 
 
-null mice and wild-type mice. All procedures were per-
formed in accordance with institutional guideline for animal re-
search at the Tokyo University of Pharmacy and Life Science.
Recombinant human IL-1
 
  
 
was purchased from Genzyme. LPS
(
 
Escherichia coli
 
 055:B5) was purchased from Difco Laboratories.
 
Mouse Bone Marrow Cultures.
 
Bone marrow cells were iso-
lated from 6-wk-old cPLA2
 
 
 
-null and wild-type mice and cul-
tured in 0.5 ml 
 
 
 
MEM containing 10% FCS at 10
 
6 
 
cells/well in
24-well plates. The cultures were fed every 3 d by replacing 0.4
ml of the old medium with fresh medium. After being cultured
for 9 d, the cultured medium was collected for the measurement
of PGE2 and the cells adhering to the well surface were stained
for tartrate-resistant acid phosphatase (TRAP). The TRAP
 
 
 
multinucleated cells containing three or more nuclei/cell were
counted as osteoclasts.
 
Measurement of PGE2 Content.
 
The concentrations of PGE2
in the cultured medium and the bone marrow fluid collected
from the mouse femurs and tibiae were determined using an en-
zyme immunoassay (EIA; Amersham Biosciences). The antibody
had the following cross-reactivity when calculated by the bound/
free ratio: PGE2, 100%; PGE1, 7.0%; 6-keto-PGF1
 
 
 
, 5.4%;
PGF2
 
 
 
, 4.3%; and PGD2, 1.0%.
 
Culture of Osteoblastic Stromal Cells and RT-PCR Analysis.
 
To
obtain osteoblastic stromal cells, mouse bone marrow cells were
isolated from the 6–8-wk-old cPLA2
 
 
 
-null and wild-type mice
and individually cultured for 2 wk in 
 
 
 
MEM containing 10%
FCS. For RT-PCR analysis, total RNA was extracted from the
cells. cDNA was synthesized from 5 
 
 
 
g total RNA by reverse
transcriptase (Superscript II Preamplification System; Life Tech-
nologies) and amplified using PCR. The primers used in PCR
for the mouse COX-2 gene were 5
 
 
 
-TCAGCCAGGCAG
CAAATCCTTG-3
 
  
 
(sense) and 5
 
 
 
-TAGTCTCTCCTAT-
GAGTATGAGTC-3
 
  
 
(anti-sense). The reaction conditions for
PCR were 26 cycles, denaturation at 94
 
 
 
C for 45 s, annealing at
60
 
 
 
C for 45 s, and extension at 72
 
 
 
C for 2 min. The primers
used in PCR for the mouse mPGES gene were 5
 
 
 
-ATGCCT-
TCCCCGGGCCTG-3
 
  
 
(sense) and 5
 
 
 
-TCACAGATG-
GTGGGCCAC-3
 
  
 
(anti-sense). The reaction conditions for
PCR were 26 cycles, denaturation at 94
 
 
 
C for 45 s, annealing at
60
 
 
 
C for 45 s, and extension at 72
 
 
 
C for 2 min. The primers
used in PCR for the mouse GAPDH gene were 5
 
 
 
-TGAAG-
GTCGGTGTGAACGGATTTGGC-3
 
  
 
(sense) and 5
 
 
 
-CATG-
TAGGCCATGAGGTCCACCAC-3
 
  
 
(anti-sense). The reac-
tion conditions for PCR were 30 cycles, denaturation at 94
 
 
 
C
for 45 s, annealing at 60
 
 
 
C for 45 s, and extension at 72
 
 
 
C for 2
min. The PCR product was run on a 1.5% agarose gel and
stained with ethidium bromide.
 
Bone Marrow Fluid.
 
6-wk-old cPLA2
 
 
 
-null and wild-type
mice were injected with LPS (5 mg/Kg of body weight) intra-
peritoneally and the femurs and tibiae were collected 1 h after the
injection. To obtain the bone marrow fluid, bone marrow cells
and cancellous bone fragments in the femurs and tibiae were in-
dividually collected with 1 ml 
 
 
 
MEM, as previously reported
(22). After centrifugation to remove the cells and bone fragments,
the supernatant was collected as bone marrow fluid for measure-
ment of PGE2.
 
Radiographic Analysis of the Femur.
 
Radiographs of the fe-
murs were taken by soft X ray (model CMB-2; SOFTEX). The
bone mineral density (BMD) of the femurs was measured by dual
X-ray absorptiometry (model DCS-600R; Aloka) as previously
reported (23). The bone mineral content of the femurs wasT
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closely correlated with the ash weight (23). The BMD was calcu-
lated by dividing the bone mineral content of the measured area
by the area. The scanned area was divided into three parts: proxi-
mal femur, midshaft, and distal femur.
 
Histological Analysis of the Femoral Cancellous Bone.
 
The distal
metaphysis of the femur was fixed with 70% ethanol and embed-
ded in glycol methacrylate, and undecalcified 3-
 
 
 
m sections were
prepared and stained for TRAP as previously reported (23). The
trabecular bone volume density (bone volume/tissue volume
[BV/TV]), the mean number of osteoclasts in each millimeter of
the trabecular bone surface (osteoclast number/bone surface,
mm
 
 
 
), trabecular separation (Tb.Sp), and trabecular thickness
(Tb.Th) were determined in the cancellous bone tissue at the sec-
ondary spongiosa of the distal metaphysis (23).
 
Statistical Analysis.
 
The data are expressed as the means 
 
 
 
SEM. The significance of differences was analyzed using Stu-
dent’s 
 
t 
 
test.
 
Results
 
PGE2 Synthesis and Osteoclast Formation in the Bone Mar-
row Cultures.
 
IL-1 acts on osteoblasts to induce PGE2
synthesis and promotes osteoclast formation in mouse
bone marrow cultures (1–5). We have previously re-
ported that cPLA2 is expressed in mouse osteoblasts and
plays an important role in the process of PGE2 produc-
tion by osteoblasts (6). To identify the role of cPLA2 in
PGE2 production and osteoclast formation, bone marrow
cells were collected from cPLA2
 
 
 
-null and wild-type
mice and cultured for 9 d with IL-1. In wild-type mice,
the addition of IL-1 to the bone marrow cultures mark-
edly induced the production of PGE2 and the formation
of TRAP
 
  
 
osteoclast-like cells (Fig. 1, A and B). In
cPLA2
 
 
 
-null mice, however, the PGE2 level in the con-
ditioned medium of the control cultures without IL-1
was lower than that in wild-type mice and the IL-1–
induced PGE2 synthesis could not be detected in the
bone marrow cultures (Fig. 1 A). In addition, the osteo-
clast formation induced by IL-1 was not detected in the
bone marrow cultures from cPLA2
 
 
 
-null mice (Fig. 1, B
and C). When PGE2 was added to the bone marrow cells,
the osteoclast formation was greatly induced in cPLA2
 
 
 
-
null mice and the level was similar to that in wild-type
mice (Fig. 1 C). Therefore, cPLA2
 
  
 
is essential for PGE2
synthesis and osteoclast formation induced by IL-1 in
mouse bone marrow cultures.
 
Production of PGE2 by Osteoblastic Bone Marrow Stromal
Cells.
 
It has been reported that bone marrow stromal cells
exhibit osteoblastic phenotype and support the differentia-
tion of osteoclast progenitor to mature osteoclasts (1, 24).
To examine PGE2 synthesis by osteoblastic cells, the bone
marrow cells were collected from cPLA2
 
 
 
-null and wild-
type mice and cultured for 2 wk to obtain the osteoblastic
stromal cells. When the stromal cells derived from wild-
type mice were treated with IL-1 and LPS, the expression
of COX-2 and mPGES mRNAs was markedly induced to
produce PGE2. However, in the stromal cells derived from
cPLA2
 
 
 
-null mice, the PGE2 production induced by IL-1
and LPS was significantly attenuated compared with wild-
type (Fig. 2). The expression of COX-2 and mPGES was
elevated by IL-1 and LPS in osteoblastic stromal cells not
only collected from wild-type mice but also from cPLA2
 
 
 
-
null mice (Fig. 2). The expression of GAPDH mRNA was
Figure 1. PGE2 production and osteo-
clast formation in mouse bone marrow cul-
tures treated with IL-1. (A) The bone mar-
row cells were collected from cPLA2 -null
and wild-type mice and cultured for 9 d
with or without 2 ng/ml IL-1. The concen-
tration of PGE2 in the cultured medium
was determined using an EIA as described in
Materials and Methods. Data are expressed
as the means   SEM of three to five mice.
*, P   0.001 versus control without IL-1;
#, P   0.001 versus IL-1–treated wild-type
group. (B) The bone marrow cells were
cultured under the conditions described
above and the cells were stained for TRAP,
a specific marker for osteoclasts. The num-
ber of TRAP  multinucleated cells contain-
ing three or more nuclei was counted. Data
are expressed as the means   SEM of three
to five mice. *, P   0.001 versus control
without IL-1; #, P   0.001 versus IL-1–
treated wild-type group. (C) The bone
marrow cells were collected from cPLA2 -
null and wild-type mice and cultured for 9 d
with 2 ng/ml IL-1 or 1  M PGE2. The cells
were stained for TRAP to detect osteoclasts.T
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similarly detected in all conditions (not depicted). These
results indicate that the impaired PGE2 production in
cPLA2 -null mice is due to the lack of the release of
arachidonic acid from the membranous phospholipids in
osteoblastic stromal cells.
LPS-induced PGE2 Synthesis in Mouse Bone Marrow.
The administration of LPS induces not only inflammation
with fever but also osteoclastic bone resorption in vivo.
PGE2 produced by various cells, such as macrophages and
mast cells, is thought to be involved in the mechanism of
LPS-elicited inflammation. To examine the LPS-induced
production of PGE2 in the bone and bone marrow in
mice, bone marrow fluid was collected from the femurs
and tibiae 1 h after LPS administration. The level of PGE2
in the bone marrow fluid was detectable and markedly ele-
vated by LPS administration in wild-type mice (Fig. 3). In
cPLA2 -null mice, the administration of LPS did not en-
hance the level of PGE2 in the mouse bone marrow (Fig.
3), indicating a key role of cPLA2  in PGE2 production by
bone and bone marrow cells in vivo.
LPS-induced Bone Loss by Increased Bone Resorption. To
determine the influence of cPLA2 -dependent PGE2
synthesis in bone loss induced by LPS administration,
cPLA2 -null and wild-type mice were injected with LPS
and the femurs were collected on day 8 for X-ray analysis.
The X-ray analysis showed that the LPS administration had
caused a marked loss of mineralized cancellous bone, espe-
cially in the distal metaphysis of the femur in wild-type
mice (Fig. 4). In cPLA2 -null mice, the loss of cancellous
bone by the LPS administration could not be seen in the
X-ray analysis (Fig. 4). To determine the change of bone
Figure 2. Expression of COX-2 and
mPGES mRNA and PGE2 production
in osteoblastic bone marrow stromal
cells treated with IL-1 and LPS. (A) The
bone marrow stromal cells were isolated
from cPLA2 -null and wild-type mice.
Cells were cultured for 3 h with or
without 2 ng/ml IL-1 to detect COX-2
and mPGES mRNA by RT-PCR. To
measure the levels of PGE2 in condi-
tioned medium, cells were cultured for
24 h with or without IL-1. (B) The
bone marrow stromal cells were cul-
tured for 3 h with or without 10 ng/ml
LPS to detect COX-2 and mPGES
mRNA by RT-PCR. To measure the
levels of PGE2 in conditioned medium,
cells were cultured for 24 h with or without LPS. The concentration of PGE2 in the cultured medium was determined using an EIA. Data are expressed
as the means   SEM of three to four wells. *, P   0.01 versus control without IL-1 or LPS; #, P   0.001 versus IL-1– or LPS-treated wild-type group.
Figure 3. The level of PGE2 in the bone marrow fluid collected from
cPLA2 -null and wild-type mice injected with LPS. To obtain the bone
marrow fluid, cPLA2 -null and wild-type mice were injected with LPS
or PBS intraperitoneally and the femurs and tibiae were collected 1 h after
the injection. Thereafter, the bone marrow fluid was prepared using 1 ml
 MEM as described in Materials and Methods, and the concentration of
PGE2 in the bone marrow fluid was determined using an EIA. Data are
expressed as the means   SEM of three to four mice. *, P   0.01 versus
control without LPS; #, P   0.01 versus LPS-treated wild-type group.
Figure 4. Lack of inflammatory bone loss induced by LPS administra-
tion in cPLA2 -null mice. Measurement of femoral BMD and soft X-ray
analysis in cPLA2 -null and wild-type mice injected with LPS. To mea-
sure the femoral BMD, cPLA2 -null and wild-type mice were injected
with LPS or PBS intraperitoneally on days 0 and 4, and the femurs were
collected on day 8 after the first injection. The BMD was measured at the
region of distal metaphysis of the excised femurs. Data are expressed as the
means   SEM of five to six mice. *, P   0.05 versus control without
LPS; #, P   0.05 versus LPS-treated wild-type group. The top shows the
radiograms of the femurs collected from the animals of each group. The
region of femoral distal metaphysis was determined by soft X-ray analysis.
Note that marked bone loss occurred in the femoral cancellous bone in
the LPS-injected wild-type mice, but not in cPLA2 -null mice.T
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mass due to LPS administration, we measured the BMD at
a distal region of the femur using cPLA2 -null and wild-
type mice. The BMD was significantly reduced by the LPS
administration at the distal metaphysis in wild-type mice,
but it was not changed at all by LPS in cPLA2 -null mice
(Fig. 4).
To define the mechanism of bone loss due to LPS ad-
ministration, histological sections of the distal femoral
metaphysis were prepared and stained for TRAP (Fig. 5
A). In wild-type mice, the bone density (BV/TV) of the
trabecular bone and the Tb.Th were significantly reduced
whereas the Tb.Sp increased with the LPS administration
(Fig. 5 B). The increase in the Tb.Sp indicates that the os-
teoclastic bone resorption was stimulated, resulting in en-
hanced intertrabecular space. In fact, the number of
TRAP  multinucleated osteoclasts significantly increased
in the trabecular bone obtained from wild-type mice
treated with LPS in vivo (Fig. 5, A and B). In cPLA2 -
null mice, however, the LPS administration did not influ-
ence the BV/TV, Tb.Sp, Tb.Th, and the number of os-
teoclasts at all (Fig. 5, A and B). These results indicate that
cPLA2  is crucial for LPS-induced osteoclastic bone re-
sorption, which results in bone loss associated with
PGE2-mediated inflammation.
Discussion
Previous studies have shown that IL-1 acts on osteoblasts
and stromal cells to synthesize PGE2 by an increased ex-
pression of COX-2 and that the production of PGE2 is es-
sential for osteoclast formation induced by IL-1 in mouse
bone marrow cultures (1–5, 25). In cPLA2 -null mice,
both PGE2 production and osteoclast formation was not
induced by IL-1 in the bone marrow cultures (Fig. 1).
Therefore, the cPLA2  gene is crucial for PGE2 synthesis
by initiating the release of arachidonic acid from membra-
nous phospholipids and regulating osteoclast formation.
The addition of PGE2 to the bone marrow cells collected
from cPLA2 -null mice markedly induced osteoclast for-
mation (Fig. 1 C), indicating that the processes for osteo-
Figure 5. Histological analyses of the femoral trabecular
bone collected from cPLA2 -null and wild-type mice in-
jected with LPS. (A) Wild-type and cPLA2 -null mice
were injected with LPS or PBS intraperitoneally on days 0
and 4, and the femurs were collected on day 8 after the
first injection to prepare the sections of femoral distal
metaphysis. The sections were stained for TRAP to detect
osteoclasts. (B) Using the TRAP-stained section shown in
A, histomorphometric analyses were performed to calcu-
late BV/TV, Tb.Sp, Tb.Th, and osteoclast number/bone
surface as described in Materials and Methods. Data are ex-
pressed as the means   SEM of three to four mice. *, P  
0.001 versus control without LPS; #, P   0.01; ##, P  
0.001 versus LPS-treated wild-type group.T
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1308 Bone Resorption in Cytosolic Phospholipase A2 –null Mice
clast differentiation followed by PGE2 production are nor-
mal in cPLA2 -null mice. The expression of COX-2 and
mPGES was elevated by IL-1 and LPS in osteoblastic stro-
mal cells not only collected from wild-type mice but also
from cPLA2 -null mice (Fig. 2). When osteoblastic stro-
mal cells collected from cPLA2 -null mice were pretreated
for 24 h with IL-1 and cultured for 8 h with or without 10
 M arachidonic acid, the level of PGE2 in the conditioned
medium was significantly elevated by the addition of
arachidonic acid (control 0.12   0.01 ng/ml; arachidonic
acid 1.25   0.13 ng/ml, P   0.01). These results indicate
that COX-2 and mPGES induced by IL-1 convert exoge-
nous arachidonic acid into PGE2 via PGH2 in the stromal
cells from cPLA2 -null mice, and that cPLA2  is essential
for the release of arachidonic acid from membranous phos-
pholipids in osteoblastic stromal cells.
Recently, a key molecule for osteoclast formation was
cloned and named as a receptor activator of nuclear factor
 B ligand (RANKL; 26–29). RANKL is expressed on
the surface of osteoblasts and bone marrow stromal
cells treated with bone-resorbing factors such as
PTH, 1 ,25(OH)2D3, PGE2, and IL-1. As IL-1 enhances
RANKL expression in the osteoblasts, it might be possible
that IL-1 directly induces osteoclast formation. However,
IL-1–induced osteoclast formation is highly dependent on
the production of PGE2 in the bone marrow cultures. The
continuous production and accumulation of PGE2 may
powerfully induce RANKL in bone marrow cells treated
with IL-1.
We found that the LPS administration markedly en-
hanced the level of PGE2 in the bone marrow fluid col-
lected from wild-type mice, but not from cPLA2 -null
mice (Fig. 3). Previous studies have indicated that macro-
phages and mast cells collected from cPLA2 -null mice
could not produce PGs after various stimuli (20, 21, 30).
Bone marrow fluid was collected from the bone marrow
cavity and distal cancellous bone area of femurs and tibiae,
indicating that PGE2 in the fluids is derived from bone
marrow cells and osteoblasts. Therefore, cPLA2  seems to
play a key role in PGE2 production by bone and bone
marrow cells in vivo.
As previously reported, cPLA2 -null mice grow nor-
mally (20) and no apparent defects nor abnormalities are
detected in the bone by soft X-ray analysis (unpublished
data). Bone loss after LPS administration was observed in
the area of distal cancellous bone of the femurs in wild-type
mice but not in cPLA2 -null mice (Figs. 4 and 5), suggest-
ing that increased PGE2 in bone and bone marrow is in-
volved in bone resorption elicited by LPS. Abu-Amer et al.
(15) reported that TNF  was involved in the osteoclast
formation induced by LPS. The production of cytokines,
including IL-1, IL-6, and TNF  might be enhanced by
LPS treatment in macrophages. Most of these cytokines in-
duce PGE2 production in osteoblasts and stromal cells, and
osteoclast formation induced by the cytokines is dependent
on PGE2 synthesis in mouse bone marrow cultures. Al-
though we cannot exclude the possibility of PGE2-inde-
pendent action of these cytokines in osteoclast formation,
cPLA2 -mediated PGE2 production is largely involved in
bone loss induced by LPS in vivo.
Previous studies have shown that LPS binds to LPS re-
ceptors, called TLR4, in macrophages and induces COX-
2–mediated PG synthesis (16, 17). In this study, LPS
greatly induced cPLA2 -dependent PGE2 production by
osteoblastic stromal cells (Fig. 2 B). In osteoblasts collected
from mouse calvaria, LPS induced COX-2– and mPGES-
mediated PGE2 production in normal C3H/HeN mice,
but not in TLR4-mutated C3H/HeJ mice (unpublished
data). Therefore, LPS may stimulate the PGE2 production
in the various cells, including macrophages, mast cells, and
osteoblasts by the TLR4-mediated mechanism.
Pharmacological study for the blockades of PGE is
closely related to the metabolic steps of PGs, which are
regulated by PLA2, COX, and PGES. Various COX in-
hibitors have been made previously, but no effective
cPLA2 inhibitor is currently available. The expression of
mPGES is greatly induced by LPS in rat peritoneal mac-
rophages and by IL-1/TNF in rat osteoblasts (13). Uematsu
et al. (31) have generated mPGES-null mice and showed
the impaired PGE production induced by LPS. Therefore,
mPGES inhibitor might be a powerful way of blocking
PGE synthesis. In addition, the PGE receptors, divided into
four subtypes (EP1, EP2, EP3, and EP4), are important in
regulating PGE action in the target cells. Using knockout
mice of respective EP and specific agonists, we reported
that PGE2 stimulates bone resorption mainly by EP4 (32,
33). Therefore, EP4 inhibitor is a candidate for the block-
ade of PGE2 action. These trials are necessary for the de-
velopment of drugs regulating several diseases associated
with inflammation.
Using cPLA2 -null mice, previous studies have shown
the role of cPLA2  in the allergic response and injury in
the lung (20, 34). Acute lung injury in a murine model
of the adult respiratory distress syndrome was significantly
reduced in cPLA2 -null mice (34). Here, we showed a
principal role of cPLA2  in PGE2 production by osteo-
blastic cells and inflammatory bone loss due to the in-
creased bone resorption. In an accompanying paper, Hegen
et al. (35) have shown that cPLA2 -null mice are resistant
to collagen-induced arthritis. Therefore, cPLA2  might
be involved in bone destruction followed by rheumatoid
arthritis. These findings suggest that the inhibition of
cPLA2 -initiated pathway might provide a possible thera-
peutic approach to inflammatory bone destruction in rheu-
matoid arthritis and periodontal diseases.
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